Lutathera synergically acts with monoclonal antibodies interfering with the inhibitory-programmed death (PD)-1/PD-L1 pathway, approved for advanced SCLC previously treated with one or more platinum based chemotherapies. This evidence concerns the gene CD274 and small cell lung carcinoma.